Documentos de Académico
Documentos de Profesional
Documentos de Cultura
Abstract
Objective: To determine whether a multiplex polymerase chain reaction (PCR)-based test could
reduce the time required for initial pathogen identification in patients in an intensive care unit
(ICU) setting.
Methods: This double-blind, parallel-group randomized controlled trial** enrolled adults with
suspected pulmonary or abdominal sepsis caused by an unknown pathogen. Both the intervention
and control groups underwent the standard blood culture (BC) testing, but additional pathogen
identification, based on the results of a LightCyclerÕ SeptiFast PCR test, were provided in the
intervention group.
1
Department of Anaesthesiology and Intensive Care
Medicine, Charité–Universitaetsmedizin Berlin, Berlin,
Germany *These authors contributed equally to the manuscript.
2
Institute for Microbiology and Hygiene Berlin, Charité– **Trial registration number: ISRCTN70694559.
Universitaetsmedizin Berlin, Berlin, Germany Corresponding author:
3
Institute of Medical Microbiology, University Hospital Dr Claudia Spies, Department of Anaesthesiology and
Münster, Münster, Germany Intensive Care Medicine, Charité–Universitaetsmedizin
4
Institute of Medical Biometry, Charité– Berlin, Campus Charité Mitte and Campus Virchow-
Universitaetsmedizin Berlin, Berlin, Germany Klinikum, 1 Augustenburger Platz, 13353 Berlin, Germany.
5
SOSTANA GmbH, Berlin, Germany Email: claudia.spies@charite.de
Creative Commons CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial
3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and
distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page
(http://www.uk.sagepub.com/aboutus/openaccess.htm).
Tafelski et al. 365
Results: The study enrolled 37 patients in the control group and 41 in the intervention group.
Baseline clinical and demographic characteristics were similar in both groups. The PCR-based test
identified a pathogen in 10 out of 41 (24.4%) patients in the intervention group, with a mean
duration from sampling to providing the information to the ICU of 15.9 h. In the control group, BC
results were available after a significantly longer period (38.1 h).
Conclusion: The LightCyclerÕ SeptiFast PCR test demonstrated a significant reduction in the
time required for initial pathogen identification, compared with standard BC.
Keywords
LightCyclerÕ SeptiFast, multiplex polymerase chain reaction, sepsis, blood culture, pneumonia,
abdominal sepsis
pathogen. We hypothesized that the rapid wards since 2006.13 All patients were
availability of the results of the PCR-based included only once even if they had multiple
pathogen identification would be accompa- episodes of sepsis during their ICU stay.
nied by a reduced delay of antimicrobial Additionally, infection onset was required to
therapy modification in critically ill patients be <72 h, to reduce the risk of detecting
with severe infections. persistent circulating DNA. Exclusion cri-
teria were age <18 years, pregnancy, police
Patients and methods custody, missing or withdrawn informed
consent or participation in another pro-
Study design spective clinical study.
This double-blind, parallel-group RCT was Patients fulfilling the inclusion criteria
undertaken at two university hospitals in were asked to provide written informed
Berlin, Germany: Charité University consent. A substantial number of critically
Hospital Campus Charité Mitte; Charité ill patients are unable to give consent due to
University Hospital Campus Charité their clinical status, their need for mechan-
Virchow Klinikum. A total of six ICUs ical ventilation, or altered mental status. In
enrolled patients between August 2010 and these cases, patients were included in the
March 2012; five anaesthesiological ICUs randomization process with a delayed con-
and one surgical ICU. This study was sent procedure. Informed consent was
approved by the local Ethics Review obtained as soon as possible, from the
Board (Ethics Commission, Charité– patient or their legal representative.
Universitaetsmedizin Berlin Campus Eligible patients 18 years old were
Charité Mitte, Berlin, Germany) and the randomized to either the control or inter-
data safety authorities; it was also registered vention group in a 1 : 1 ratio, according to
with the International Standard consecutive sample processing by the
Randomized Controlled Trial number Institute for Microbiology and Hygiene
ISRCTN70694559. Written informed con- Berlin, Charité–Universitaetsmedizin Berlin,
sent was obtained from every included Berlin, Germany. Randomization was
patient or their legal representative. achieved using computer-generated random
numbers and performed in blocks of four.
The randomization scheme was not known
Patient inclusion and randomization to the treating physicians on the ICUs. To
Patients were eligible for study inclusion minimize the risk of bias, allocation was
when they presented with signs of sepsis of blinded to all clinical study participants and
suspected abdominal or pulmonary origin, staff members on the ICU. Furthermore, to
caused by an unknown pathogen when BC achieve maximum allocation concealment,
diagnostics were indicated. Sepsis was treating physicians on the ICUs were not
defined as suspected or proven infection aware of group assignment until the results
causing systemic inflammation with at least of the multiplex PCR analysis were available
two of the following: (i) leucocyte count <4 and communicated to the study ICU wards.
or >12 /nl; (ii) body temperature <36 C or
fever >38 C; (iii) tachypnoea >20/min or
Microbiological procedures, study
hyperventilation (paCO2 <32 mmHg); (iv)
tachycardia >90 bpm.5 Infections were
intervention, data collection
defined by the treating physicians using Microbiological diagnostics were performed
standardized criteria for infection manage- on participating ICU wards, whenever the
ment implemented on the participating patient’s clinical condition indicated
Tafelski et al. 367
to participate in the study or the patient Escherichia coli, Candida parapsilosis and
experienced rapid clinical deterioration and Candida albicans. In the intervention group,
subsequent death with no legal representa- corresponding BCs grew pathogens in five of
tive being nominated. According to the 41 (12.2%) patients. In one BC sample,
institutional review board vote, all data S. epidermidis was detected that was not
from these 22 excluded patients were found by the LightCyclerÕ SeptiFast PCR
deleted. As a consequence, the study fol- test. In all of the other cases, all of the
lowed-up and analysed 78 patients: 37 in the BC results were also detected by the
control group and 41 in the intervention LightCyclerÕ SeptiFast PCR test.
group (Figure 1). In the control group, BCs were positive in
Baseline demographic and clinical char- seven of 37 patients (18.9%) growing
acteristics did not differ significantly S. epidermidis, E. faecium, E. faecalis and
between the two groups (Table 1). The S. aureus (Table 2). In the post-hoc
most common clinical condition was sepsis LightCyclerÕ SeptiFast PCR test of
of pulmonary origin, which was observed in collected samples, eight pathogens were
78% (29 of 41) of patients in the control identified (E. coli, E. faecium, E. faecalis,
group and 63% (26 of 41) in the intervention Streptococcus pneumoniae, S. aureus and
group. S. epidermidis). In one case with BCs grow-
In 10 of 41 (24.4%) patients in the ing two pathogens (E. faecalis and
intervention group, the LightCyclerÕ S. epidermidis), the LightCyclerÕ SeptiFast
SeptiFast PCR test identified one of the PCR test only identified E. faecalis.
following pathogens in the bloodstream The concordance rate between the BC
(Table 2): Staphylococcus aureus, results and those of the LightCyclerÕ
Pseudomonas aeruginosa, Klebsiella spp., SeptiFast PCR test were analysed for
Enterococcus faecium, Enterobacter spp., the intervention and control groups.
Allocaon1:1
Analysis
Figure 1. Consort flow diagram for patient enrolment into a randomized controlled clinical trial that
evaluated whether rapid pathogen identification (using a multiplex polymerase chain reaction test) reduced
time required for the initial pathogen identification and subsequent therapy modification to target the specific
pathogen, in patients treated in intensive care units.
370 Journal of International Medical Research 43(3)
Table 1. Baseline clinical and demographic For analysis of the test performance of
characteristics of patients treated in intensive care the LightCyclerÕ SeptiFast PCR test, BC
units (ICUs), randomized to undergo either a results were used as the diagnostic gold
multiplex polymerase chain reaction test for initial standard for detecting bacteraemia. The
pathogen identification (intervention group) or resulting sensitivity for a positive
standard blood culture analysis (control group).
LightCyclerÕ SeptiFast PCR test result
Control Intervention was 58.3% (seven of 12 samples) with a
group group corresponding specificity of 74.2% (49 of 66
Parameter n ¼ 37 n ¼ 41 samples).
For the main study endpoint, the dur-
Age, years 59 (47–67) 67 (53–74)
ation between biological sampling and avail-
ICU stay, days 32 (16–57) 34 (13–65)
ability of microbiological results by
Hospital stay, days 37 (20–76) 53 (33–79)
Duration of 608 (246–990) 522 (76–1206) telephone to the ICU physicians was calcu-
ventilation, h lated. In the intervention group, this process
Female sex 13 (35) 15 (37) took 15.9 5.9 h compared with
SAPS II on 47 (34–65) 40 (32–50) 38.1 11.6 h in the control group
admission (P < 0.001). Antimicrobial therapy modifi-
Immune 6 (16) 6 (15) cations resulting from feedback from the
suppression microbiological tests are summarized in
Alcohol abuse 5 (14) 4 (10) Table 3. Microbiological diagnostic infor-
Origin of sepsis mation lead to four therapy adaptations
Abdominal 8 (22) 15 (37)
immediately after the telephone call in the
Pulmonary 29 (78) 26 (63)
intervention group (9.8%) and to five
Septic shock 25 (68) 20 (49)
ICU mortality 8 (22) 7 (17) changes in the control group (13.5%). For
these patients, the mean SD time from
Data presented as median (25–75 percentile) or n (%). initially drawing blood to adaptation of
SAPS II, Simplified Acute Physiology Score II.15 antimicrobial treatment was 18.8 5.6 h in
No significant between-group differences (P 0.05).
the intervention group compared with
38.3 14.5 h in the control group (Table 4).
Based on these findings, the time required
Seven samples were positive for the same for therapy modification in the intervention
pathogen in both the LightCyclerÕ group was reduced by 19.5 h compared with
SeptiFast PCR test and the corresponding the control group, although the difference
BC; 49 samples were validated as negative between the two groups was not statistically
for both assays. In six control-group sam- significant.
ples analysed after short-term frozen stor- For the reduction in the time to anti-
age, the LightCyclerÕ SeptiFast PCR test microbial therapy modification, this study
result had a technical signal in the test reached a power of 55% with an exact alpha
summary and was not validated: in two of P ¼ 0.063. Based on these findings, a
samples, no pathogens were detected but the second a priori power analysis was per-
internal control was also negative; in four formed to assess the sample size for a
samples, the negative control channel was future confirmatory RCT evaluating this
positive, indicating potential system con- endpoint. With a conservative assumption
tamination. None of these patients had a of 80% power and a relevant effect size of
pathogen detected in BCs. These results 1.691, a nonparametric unpaired Wilcoxon
demonstrated a concordance rate of 56 out test analysis would be able to determine a
of 78 analysed samples (71.8%). significant difference between the two study
Tafelski et al. 371
Table 2. Results of standard blood culture (BC) microbiological analyses, LightCyclerÕ SeptiFast poly-
merase chain reaction (PCR) tests and corresponding clinical pictures for patients treated in intensive care
units and randomized to undergo either a multiplex polymerase chain reaction test for initial pathogen
identification (intervention group) or standard BC analysis (control group).
Intervention group
Pseudomonas aeruginosa P. aeruginosa Pneumonia, PCR and BC pathogen also detected
in TBS cultures
Escherichia coli E. coli Suspected pneumonia, PCR and BC pathogen
detected in TBS cultures
Candida parapsilosis C. parapsilosis Suspected pulmonary infection; candidaemia
identified in multiple BCs; C. parapsilosis
detected in TBS cultures
C. albicans C. albicans Suspected abdominal sepsis; candidaemia
identified in multiple BCs
Staphylococcus aureus Pneumonia, multiple BCs remained negative,
S. aureus detected in TBS cultures
P. aeruginosa Suspected abdominal infection, TBS and multiple
BC samples remained negative
Klebsiella pneumoniae/oxytoca Pneumonia, BCs and TBS, and pleural puncture
secretion remained negative
E. coli Pneumonia, multiple BCs remained negative,
TBS showed E. coli growth
Enterococcus faecium Abdominal infection, BCs series remained
negative, intraoperative samples identified
Enterococcus spp.
Enterobacter cloacae/aerogenes Pneumonia, BCs remained negative, TBS culture
negative
S. epidermidis Pneumonia, no bacterial growth in TBS culture,
three independent BCs grew S. epidermidis,
catheter-related infection suspected (devices
were changed)
Control group
E. faecalis S. epidermidis, Pneumonia, E. faecalis PCR validated by BC.
E. faecalis S. epidermidis detected in one BC, not detected
in PCR, clinically judged as contamination
S. epidermidis S. epidermidis Pneumonia, BC and PCR results validated by
additional BCs, catheter-related infection
suspected (devices were changed)
E. faecium E. faecium Abdominal infection, BC and PCR results
validated by pathogen identification E. faecium
in ascites aspirate
S. aureus Pneumonia, BC remained negative, TBS and BAL
culture identified S. aureus
S. aureus Pneumonia, multiple BCs, TBS, BAL cultures
remained negative
(continued)
372 Journal of International Medical Research 43(3)
Table 2. Continued.
groups if they included nine patients with intervention group, both of which were
therapy modifications in each study arm validated with subsequent standard BC
(i.e. a total of 18 patients). diagnostics. PCR-based methods might be
most beneficial for patients with a high
incidence of fungal infections or ongoing
Discussion antibiotic therapy.16
This double-blind, parallel-group RCT Results from the standard BCs and the
demonstrated a significant reduction in the LightCyclerÕ SeptiFast PCR test were con-
time required for initial pathogen identifica- cordant in seven of 12 BC positive cases (i.e.
tion using a multiplex PCR detection plat- the gold standard). Therefore, the
form, compared with standard BC LightCyclerÕ SeptiFast PCR test had a
diagnostics, in ICU patients with clinical sensitivity of 58.3%. The specificity of the
sepsis of pulmonary and abdominal origin. LightCyclerÕ SeptiFast PCR test was 74.2%
Most importantly, this very early identifica- (49 of 66 samples). Other clinical research
tion of the causative pathogen within 24 h of showed a sensitivity of 50–100%, even with
admission was integrated into the clinical low bacterial counts of 3 colony forming
decision-making process and resulted in units/ml, depending on the species.14
earlier modifications of empirical antimicro- Although authors reported a specificity of
bial therapy. Using the LightCyclerÕ 100%, contamination during sampling and
SeptiFast PCR test shortened the duration sample workflow might be an issue.14 This
from sampling to availability of microbio- difficulty is also a well-described phenom-
logical results by 22.2 h. Two cases of enon for standard BC diagnostics and a
candidaemia were detected in the contamination rate of 5% is reported for
Tafelski et al. 373
Intervention group
Candida albicans Piperacillin/tazobactam Fluconazole
Fluconazole
Candida parapsilosis Fluconazole Voriconazole
Tigecycline
Ceftazidime
Staphylococcus aureus Piperacillin/tazobactam Gentamicin
Ciprofloxacin Ceftriaxone
Vancomycin
Pseudomonas aeruginosa Piperacillin/tazobactam Ciprofloxacin
Ciprofloxacin Meropenem
Sultamicillin
Control group
S. epidermidis Piperacillin/tazobactam Piperacillin/tazobactam
Tobramycin Tobramycin
þ Enterococcus faecalis Vancomycin
S. epidermidis Meropenem Meropenem
Ciprofloxacin Vancomycin
S. epidermidis Piperacillin/tazobactam Piperacillin/tazobactam
Clarithromycin Clarithromycin
Vancomycin
S. epidermidis Cefuroxime Vancomycin
S. epidermidis Piperacillin/tazobactam Piperacillin/tazobactam
Clarithromycin Clarithromycin
Linezolid
Table 4. Results of time analyses for patients being treated in intensive care units, randomized to undergo
either a multiplex polymerase chain reaction (PCR) test for initial pathogen identification (intervention group)
or standard blood culture analysis (control group).
Duration from sampling to Gram staining in positive 38.1 11.6 41.8 12.9
blood cultures, ha
Duration from sampling to positive PCR result, ha – 15.9 5.9
Duration from sampling to therapy modification, hb 38.3 14.5 18.8 5.6
the ICU setting.17 A Japanese group The application of fast pathogen detection
reported a higher positive rate using a methods might enable physicians to tailor
PCR-based method than with BC, but antibiotic prescribing to individual patients
demonstrated a slightly higher sensitivity in the future.
and specificity than was observed in this Although the LightCyclerÕ SeptiFast
current study.18 The sensitivity and specifi- PCR test was expected to reduce the time
city of the LightCyclerÕ SeptiFast PCR test to initial pathogen diagnosis based on the
in this current study were similar to those methodological characteristics of the test,
reported in recent studies conducted in the effects on the subsequent clinical deci-
Germany and Spain.19,20 The Spanish sion making process was not predictable a
group evaluated patients with complicated priori. A reduction in the time to pathogen
bloodstream infections and reported a sen- identification through the use of PCR-based
sitivity of 56.0% and a specificity of technology has been previously reported,
79.5%.20 It should be noted that in all but the study used an open design with the
these studies including the current physicians knowing the results for all
study,14,18–20 BC results were used as the patients and them not reporting the time
reference gold standard, even though the until they received the results of the BCs.19
sensitivity of this standard diagnostic meth- PCR-based methods might be particularly
ods is also limited.7 As shown in Table 2, useful in patients pretreated with antibiotics,
there were cases with negative BCs but as reported by a Japanese group.18 The best
positive PCR-based pathogen identification. results in terms of rapid pathogen identifi-
These pathogens were also identified in cation would probably require the combin-
other microbiological samples. Results ation of both standard BC methods and
from other biological samples, such as PCR-based technololgy.21,22 There remains
urine and tracheobronchial or abdominal an element of uncertainty about PCR-based
drainage secretions, may be included in the pathogen identification because circulating
clinical assessment of a specific patient’s DNA does not necessarily mean that the
condition. In some cases, BCs may have patient is infected with the pathogen. In this
shown false-negative results, but analysis of current study, the risk of detecting persistent
diagnostic performance remains limited to circulating DNA was reduced by only
the reference diagnostics. including patients in the first 72 h after the
Timely identification of the causative onset of sepsis.
pathogen provides important information This study had a number of strengths and
to ICU physicians that can be used to guide limitations. The strengths included external
antimicrobial therapy usage while also redu- patient randomization, which included allo-
cing nonessential use of antimicrobial cation concealment and separation of clin-
agents. In this current study, two cases of ical care teams from the study team, to
unsuspected candidaemia were identified maximize the reduction in bias.
using the LightCyclerÕ SeptiFast PCR test. Furthermore, the study groups were similar
In this context, a quasi-experimental, before with regard to their baseline demographic
and after, observational cohort study and clinical characteristics. The limitations
demonstrated that a conservative strategy included the fact that the a priori scenario
with prompt diagnostics and reluctant anti- assumed that the availability of the multi-
biotic prescribing was associated with plex PCR-based test was equal to that of
reduced overall mortality in ICU patients.12 standard BC diagnostics, which it was not.
These authors also reported that their As a consequence of the limited availability
microbiological results within 24 h.12 of trained staff to undertake multiplex
Tafelski et al. 375
PCR-based test during evenings and week- outcomes should be addressed in future
ends, and to ensure an adequate comparison trials, to demonstrate if advantages of
of the two diagnostic techniques, patients rapid multiplex PCR-based pathogen diag-
were only enrolled into the study between nosis lead to clinical benefits for patients.
18.00 h and 06.00 h because the multiplex This trial was designed to provide an
PCR-based test was only available for 12 h estimate of the number of patients that
during the daytime on weekdays. This would be needed to be included in a con-
assumption was made because of the recent firmatory RCT with a comparable design in
technical developments in the field. future. Based on these findings, with a power
Multiplex PCR technology is used in plat- of 80%, 18 patients with therapy modifica-
forms with improved automation and has tions based on rapid PCR-based diagnostic
also been developed for point-of-care set- information would be needed to demon-
tings. In contrast, the workflow for standard strate a statistically significant difference on
BCs allowed for immediate growth of micro- a two-sided alpha level of 5%. If there was a
organisms and automated incubation was low pathogen detection rate of 10% in the
also available during the night and at week- population, 180 patients would be required.
ends. This limited enrolment period led to a In conclusion, multiplex PCR-based
substantial number of patients not fulfilling identification of microbial pathogens might
the inclusion criteria because of having represent a fundamental change in the way
already had BCs taken during the regular that physicians manage bacterial and fun-
morning shifts on the ICU ward. The limited gal infections. PCR-based technology is
enrolment period also meant that patient developing quickly in this field, and sample
recruitment lasted longer than initially processing and workflow have already
expected. As a result of this particular improved compared with the LightCyclerÕ
limitation, generalizability of these findings SeptiFast PCR test platform used in this
is limited to the precondition that the study.25 With the innovations being made
multiplex PCR-based test was only available and the growing clinical availability of these
within a distinct time frame. Compared with PCR-based techniques, a time requirement
previous trials assessing specific clinical of <6 h from sampling to pathogen identi-
settings,23,24 this current study focused on fication could mean that infection man-
a broader target population, which was agement shifts from modifying empirical
recruited from six different ICUs at two therapy to providing pathogen-specific tar-
study sites and represented a broad spec- geted regimens right from the initiation of
trum of patients admitted to postoperative therapy. However, more clinical data are
ICUs. It was not in the scope of this current required to prove the reliability of PCR-
study to evaluate different PCR-based diag- based technology, as well as its usefulness,
nostic techniques that are currently avail- in different clinical settings.
able.25 The current study only aimed to
assess the use of DNA-based pathogen
detection using one specific assay, the Declaration of conflicting interest
LightCyclerÕ SeptiFast PCR test. All authors declare that they have no conflicts of
Furthermore, this trial did not evaluate the interest concerning the specific subject of this study.
economic impact of this innovative technol- I.N. and S.T. received lecture fees from Roche
ogy. Similarly, the impact on patient Deutschland GmbH and Pfizer Deutschland
outcomes is one of the most important GmbH. C.S. received lecture fees or grants for
aspects, but this was not investigated in other projects from Abbott, Aspect, Baxter,
this current study. Morbidity and mortality Deltex, Care Fusion, Fresenius, Hutchinson,
376 Journal of International Medical Research 43(3)
Köhler, MSD, MCN, Novartis, Sysmex, Pajunk, 7. Shafazand S and Weinacker AB. Blood
Köhler Chemie, Essex Pharma, Pfizer and GSK. cultures in the critical care unit: improving
utilization and yield. Chest 2002; 122:
Funding 1727–1736.
8. Breitkopf C, Hammel D, Scheld HH, et al.
This study was supported by a restricted grant,
Impact of a molecular approach to improve
from Roche Deutschland GmbH, which covered
the microbiological diagnosis of infective
laboratory transportation and microbiological heart valve endocarditis. Circulation 2005;
diagnostic materials. 111: 1415–1421.
9. Bloos F, Hinder F, Becker K, et al.
Acknowledgements A multicenter trial to compare blood culture
We would like to thank the patients and their with polymerase chain reaction in severe
relatives for their willingness to participate in human sepsis. Intensive Care Med 2010; 36:
this study in a difficult clinical situation. Also, we 241–247.
would like to gratefully mention Sara Casu MD, 10. Bravo D, Blanquer J, Tormo M, et al.
Susanne Heim MD, Robert Powollik MD, and Diagnostic accuracy and potential clinical
value of the LightCycler SeptiFast assay in
Andreas Rothbart MD for their support in this
the management of bloodstream infections
study.
occurring in neutropenic and critically ill
patients. Int J Infect Dis 2011; 15: e326–e331.
References 11. Tsalik EL, Jones D, Nicholson B, et al.
1. Vincent JL, Rello J, Marshall J, et al. Multiplex PCR to diagnose bloodstream
International study of the prevalence and infections in patients admitted from the
outcomes of infection in intensive care units. emergency department with sepsis. J Clin
JAMA 2009; 302: 2323–2329. Microbiol 2010; 48: 26–33.
2. Reinhart K, Daniels R, Kissoon N, et al. The 12. Hranjec T, Rosenberger LH, Swenson B,
burden of sepsis – a call to action in support of et al. Aggressive versus conservative initi-
World Sepsis Day 2013. J Crit Care 2013; 28: ation of antimicrobial treatment in critically
526–528. ill surgical patients with suspected intensive-
3. Liesenfeld O, Lehman L, Hunfeld KP, et al. care-unit-acquired infection: a quasi-
Molecular diagnosis of sepsis: new aspects experimental, before and after observational
and recent developments. Eur J Microbiol cohort study. Lancet Infect Dis 2012; 12:
Immunol (Bp) 2014; 4: 1–25. 774–780.
4. Kumar A, Roberts D, Wood KE, et al. 13. Tafelski S, Nachtigall I, Deja M, et al.
Duration of hypotension before initiation of Computer-assisted decision support for
effective antimicrobial therapy is the critical changing practice in severe sepsis and septic
determinant of survival in human septic shock. J Int Med Res 2010; 38: 1605–1616.
shock. Crit Care Med 2006; 34: 1589–1596. 14. Lehmann LE, Hunfeld KP, Emrich T, et al.
5. Dellinger RP, Levy MM, Rhodes A, et al. A multiplex real-time PCR assay for rapid
Surviving Sepsis Campaign: international detection and differentiation of 25 bacterial
guidelines for management of severe sepsis and fungal pathogens from whole blood
and septic shock, 2012. Intensive Care Med samples. Med Microbiol Immunol 2008; 197:
2013; 39: 165–228. 313–324.
6. Reinhart K, Brunkhorst FM, Bone HG, et al. 15. Le Gall JR, Lemeshow S and Saulnier F.
Prevention, diagnosis, treatment, and follow- A new Simplified Acute Physiology Score
up care of sepsis. First revision of the S2k (SAPS II) based on a European/North
Guidelines of the German Sepsis Society American multicenter study. JAMA 1993;
(DSG) and the German Interdisciplinary 270: 2957–2963.
Association for Intensive and Emergency 16. Rath PM, Saner F, Paul A, et al. Multiplex
Care Medicine (DIVI). Anaesthesist 2010; 59: PCR for rapid and improved diagnosis of
347–370. (in German, English Abstract). bloodstream infections in liver transplant
Tafelski et al. 377